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A Ab bs st tr ra ac ct t
Hereditary cancers are thought to account for around 5% of cancers, particularly breast/ovarian and colorectal
cancers. In India there is a paucity of data on hereditary cancers and the mutations in some of the common
genes linked to hereditary cancers, such as BRCA1, BRCA2, hMSH2 and hMLH1. The country's first
comprehensive hereditary cancer clinic was established in February 2002. The article describes the organization
and running of the Clinic. It also discusses some of the social issues relevant to the given population in running
the Hereditary Cancer Clinic. 
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I In nt tr ro od du uc ct ti io on n
Although the cancer burden is very high in India,
the incidence of cancer is lower than in the West. In
Chennai (formerly Madras), the population-based
cancer registry has recorded a crude incidence rate
(CIR) of 90.5/100,000 and 102.7/100,000 in males
and females, respectively [1], which is nearly 3 – 4 fold
lower than that seen in the West (464.6/100,000 and
377.9/100,000 in males and females, respectively)
[2]. In women, the most common cancers seen in
Chennai are breast cancer (CIR 26.09/100,000),
cervix cancer (CIR 23.37/100,000), stomach cancer
(CIR  5.14/100,000)  and  ovarian  cancer  (CIR
5.14/100,000). The incidence of colo-rectal cancers
is much lower than in the West (2.25/100,000 in men
and 1.6/100,000 in women) [1]. Around 5% of
cancers are considered to be due to a hereditary
background. Until a few years ago there were very few
data available on the hereditary cancers in the Indian
population and the mutation rates in the common
hereditary cancers, such as BRCA1, BRCA2, MSH2
and MLH1 [3-6]. Again due to the ethnic diversity,
studies  done  in  one  part  of  India  may  not  be
representative of the whole country. 
The  Indian  population  is  also  unique  in  that
marriages usually occur within a given caste and
sometimes within the family (consanguineous marriage)
(uncle-niece marriages are common in South India).
This leads to the potential for relative inbreeding and
possible segregation of genes. In view of the lack of
information on hereditary cancer incidence and the
types of mutation, the first comprehensive Hereditary
Cancer Detection and Prevention Programme (HCDPP)
in India was started in February 2002 at the CancerH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 166
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Institute (WIA), Chennai. The Programme has the
following components: 
1. The Population-Based Hereditary Cancer Registry. 
2. The Hereditary Cancer Clinic (HCC). 
3. The Mutation Analysis Laboratory. 
This article will discuss the organization and running
of the Hereditary Cancer Clinic at the Cancer Institute
(WIA). 
O Or rg ga an ni iz za at ti io on n   
o of f   t th he e   H He er re ed di it ta ar ry y   C Ca an nc ce er r   C Cl li in ni ic c
D Da ay y   a an nd d   t ti im me e: :   The Hereditary Cancer Clinic is run
as a free clinic once a week on Saturdays between 8.30
am and 1.00 pm. On the days when there are more
patients the Clinic runs until all the patients are seen. 
P Pe er rs so on nn ne el l: :   The Clinic is manned by an oncologist
(T.R.),  a doctoral  student  (N.S.)  and  a part-time
Psychologist (E.V.). The oncologist is involved in the
clinical examination, analysis of the information obtained
from the patients regarding their family and their personal
history, assessing the eligibility of the proband for gene
testing, counselling the proband/patients and their
families with regard to their cancer risk, the intervention
procedures and preventive measures available, and after
gene testing the announcement of the results and the
investigations/preventive measures that need to be
followed by the proband/patient. The doctoral student
collects the questionnaire-based information from the
proband, draws the pedigree chart, and is responsible
for data entry, sample collection and analysis. The
part-time psychologist evaluates the patients at least once
before the gene testing results are announced. 
C Ch ha ar rg ge es s   f fo or r   t th he e   s se er rv vi ic ce e: : The entire service, including
mutation analysis where indicated, is provided free of
charge. 
P Pr ro oc ce ed du ur ra al l   d de et ta ai il ls s: :   
I. Questionnaire-based data collection: 
The questionnaire is a modified version of the
format presented in Cancer and Genetics. A manual
for clinicians and their patients, 1998 [7]. All probands
are required to provide as much information as
possible about their families, personal history and diet
history. If the proband is educated and is unable to
provide all the information at the time of interview, he
or  she  is  encouraged  to  take  a copy  of  the
questionnaire and complete it in consultation with their
elders in the family and mail it to us. The questionnaire
used in the Clinic is appended as a Word document.
On average the administration of the questionnaire
takes 20 minutes. All the probands with cancer or
a history of cancer in the family (first- or second-degree
relatives) are administered the questionnaire. The
exception to this is individuals who attend the Clinic
either to obtain more information on the hereditary
cancers or those with only a distant relative (third
degree or beyond) with cancer or those who are
unwilling to provide information about their family. 
II. Initial counselling: 
The oncologist analyses the information provided
and  requests  additional  information  if  indicated,
particularly with regard to types of cancers in the family.
The ability to provide additional information is always
better in the upper socio-economic group compared
to the lower socio-economic group. A complete physical
examination is performed, following which, based on
the information provided, the proband is counselled
with regard to the possibility of the cancer seen in him
or in his family being hereditary in origin. If there are
specific genes linked with the cancer/s seen in the family,
the proband is offered gene testing if the eligibility
criteria for gene testing are satisfied. Probands are
counselled with regard to preventive strategies, early
detection approaches and therapeutic interventions
available. They are also informed about the option of
predictive testing in their siblings and children. 
The eligibility criteria for gene testing are given
below. 
1. H He er re ed di it ta ar ry y   b br re ea as st t/ /o ov va ar ri ia an n   c ca an nc ce er r   
a. Early onset of breast cancer (at or less than 35
years of age) 
b. Two cases of breast cancer diagnosed under the
age of 50 years
c. Three cases of breast cancer diagnosed under
60 years of age 
d. Four or more cases of breast cancer diagnosed
at any age
e. Presence of breast and ovarian cancer in the
family or in the same individual 
f. Male breast cancer with a relative (of either sex)
with breast cancer. 
2. H HN NP PC CC C
B Be et th he es sd da a   g gu ui id de el li in ne es s are used [8]
a. Families meeting the Amsterdam criteria
b. Individuals with two HNPCC-related cancers
c. Individuals  with  colorectal  cancer  and
a first-degree relative with colorectal cancer and/or
HNPCC-related  extra-colonic  cancers  or
a colorectal adenoma, in which one of the cancers
was diagnosed before 45 years of age and
adenoma was diagnosed before 40 years of age
d. Individuals with colorectal or endometrial cancer
diagnosed before 45 years of ageH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(4) 167
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e. Individuals with right-sided colon cancer with
undifferentiated pattern diagnosed <45 years of
age. 
f. Individuals with signet ring type C-R cancer Dx
<45 years of age
g. Individuals with adenoma diagnosed under 40
years of age. 
3. M Mu ul lt ti ip pl le e   E En nd do oc cr ri in ne e   N Ne eo op pl la as si ia a   ( (M ME EN N) )   2 2 [ [9 9] ]
a. MEN 2A
b. MEN 2B
c. Familial Medullary Thyroid Carcinoma (FMTC) 
4. Li-Fraumeni (LFS) and Li-Fraumeni Like (LFL)
Syndrome
Li and Fraumeni defined criteria for LFS as follows
[10,11]: 
a. A proband  diagnosed  with  sarcoma  when
younger than 45 years AND
b. A first-degree relative with any cancer diagnosed
when younger than 45 years 
A AN ND D
c. Another first- or second-degree relative of the same
genetic lineage with any cancer diagnosed when
younger than 45 years or sarcoma diagnosed at
any age. 
Eeles' definition of LFL (Eeles, 1995) 
Two first- or second- degree relatives with LFS-related
malignancies at any age. 
III. Informed  consent  and  providing  of  blood
sample for gene testing: 
All patients considered eligible for gene testing were
required to provide an informed consent for willingness
to have a sample of blood and tumour tissue provided
and willingness to have the gene testing done. Only
after the signing of the informed consent were blood
samples drawn for gene testing. 
In patients who had had their surgery performed
elsewhere, paraffin blocks were requested. 
IV. Gene testing
At present, gene testing is being performed for
BRCA1, BRCA2, MSH2, MLH1, RET and p53. The
methodology for mutation analysis for BRCA1 and
BRCA2 [5] and for hMSH2 and hMLH1 [6] has been
as described, using the PCR-dHPLC. RET and p53 are
studied using PCR followed by direct sequencing of the
PCR products [12,13,14]. 
V. Follow-up
Once the gene test results are ready, a note is
inserted in the case records of the patients asking the
treating physician to refer the patient to the Hereditary
Cancer Clinic. Patients who had been referred from
outside the Cancer Institute (WIA) were informed by
a letter to their contact address that the gene test results
were ready and that they could visit the Clinic to know
the results. Prior to announcing the results, the proband
was asked to provide an informed consent that they
would like to know their gene test results. On obtaining
the consent, a psychological assessment was made
using a long form of general health questionnaire and
the Hamilton rating scale for depression. The test results
were then announced and an interpretation of the results
was made. The proband and the family were counselled
about their risk for a second primary, their siblings and
children's risk of developing cancer, the strategies for
cancer  prevention,  regular  monitoring  and  early
detection. If a deleterious mutation was detected then
predictive testing for the unaffected members in the
family (first and second degree) was offered. 
Patients with deleterious mutations were advised
closer follow-up and the treating physicians were
informed about the results and suggested line of
management. The patients were advised once in six
monthly reviews in the Hereditary Cancer Clinic. 
R Re es su ul lt ts s
The number of cases/families registered in the
Hereditary Cancer Clinic is given in Table 1. The details
of the families/individuals registered are given in Tables
2 and 3. Among the hereditary cancer families,
hereditary breast and/or ovarian cancers predominate
in the Clinic (15%). There are also a large number of
T Ta ab bl le e   1 1. . Number of cases registered in the HCC
Total number of cases registered in HCC 442
Number of families with proband affected with cancer 342
Number of families without proband affected with cancer 100
W Wi it th h   P Pr ro ob ba an nd d   A Af ff fe ec ct te ed d
Number of families with more than 2 members affected  73
with proband affected 
Number of families with 2 members affected  107
with proband affected
Proband with multiple cancers 6
Early onset cancers 156
W Wi it th ho ou ut t   P Pr ro ob ba an nd d   A Af ff fe ec ct te ed d
Number of families with more than 2 members affected  42
without proband being affected.
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early onset cancers (156/342) (45.6%), particularly
breast (≤ 35 years of age; 17.3%) and colorectal (≤ 45
years of age; 25.4%), registered in the Clinic. The
'Others' group includes cervical cancer, tobacco-related
cancers, gastric cancer, leukaemia, etc., in the family
involving more than one family member. 
Gene testing has been performed for 80 hereditary
breast and/or ovarian cancers and/or early onset
breast  or  ovarian  cancers,  and  12  deleterious
mutations or mutations of probable significance were
detected (15%). Among the 76 HNPCC syndrome
patients  included  as  per  the  Bethesda  criteria,
9 deleterious mutations or mutations of probable
significance were detected. The MEN 2B patient was
found to have the classic mutation in the RET oncogene
in Ex16- c. 2943T >C; p. M918T. Of the two LFS and
four LFL syndrome families studied for p53 mutation,
both the LFS and one of the LFL were found to carry
a germline mutation in the p53 gene (Table 4). 
The acceptability for gene testing was 95.6% with
194 of the 203 individuals offered gene testing
providing an informed consent for the gene testing and
a blood sample. However, of the 21 patients with
a deleterious  mutation  or  mutation  of  probable
significance in the hereditary breast and/or ovarian
cancers, early onset breast or ovarian cancers and the
HNPCC syndrome, only 8 (38%) opted to know the
result (Table 5). Among the 8, only 2 families wanted
to have predictive testing for their siblings or children. 
D Di is sc cu us ss si io on n
This  is  the  first  report  on  the  functioning  of
a comprehensive hereditary cancer clinic in India. The
Clinic currently draws patients not only from the
southern states of Tamil Nadu, Andhra Pradesh and
Karnataka, but patients are also being referred from
New Delhi and other parts of the country. When the
idea of a hereditary cancer clinic was mooted in the
Institute, there were concerns regarding the utilization
of such a service from the conservative population.
T Ta ab bl le e   2 2. .   Details of the type of hereditary cancers seen in families
which also had the proband affected
Hereditary Breast and Ovarian Cancer 50
Hereditary Ovarian Cancer 3
Hereditary Non-Polyposis Colorectal Cancer 12
Early onset breast cancer 59
Early onset colorectal cancer 87
Early onset ovarian cancer 6
Early onset endometrium cancer 2
Early onset stomach cancer 1
Early onset bladder cancer 1
Li-Fraumeni Syndrome 2
Li-Fraumeni-like syndrome 6
T Ta ab bl le e   3 3. .   Details of the type of hereditary cancers seen in families in
which the proband was not affected
Hereditary Breast and Ovarian Cancer 14
Hereditary Non-Polyposis Colorectal Cancer 4
others 82
T Ta ab bl le e   4 4. . Gene testing and results
BRCA1 & BRCA2 80
deleterious or mutation of probable significance detected  12
in BRCA1 or BRCA2
hMSH2 & hMLH1 76
deleterious or mutation of probable significance detected  9
in hMSH2 & hMLH1
RET 2
deleterious or mutation of probable significance  1
detected in RET
p53 & CHEK2 (1100delC) 6
deleterious or mutation of probable significance  3
detected in p53
T Ta ab bl le e   5 5. .   Acceptability for gene testing HBC/HBOC and HNPCC
No. of patients who were offered gene testing 203
No. of patients who declined gene testing 9
No. of patients with a deleterious mutation/mutation  1/21
of probable significance, who declined treatment 
at the Institute after the initial diagnosis and registration 
in the hereditary cancer clinic
No. of patients with deleterious mutation/mutation  12/21
of probable significance, who did not want to know 
the results, in spite of regular follow-up at the Institute
No. of patients with deleterious mutation/mutation  8/21
of probable significance, who took the results
Number of patients who wanted predictive testing  2/8
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The foremost concern was that a family would try to
avoid reference to cancer in the family, particularly with
regard to the marriage of their children and the
potential 'stigma' of being from a cursed family. The
second concern was with regard to the reliability of the
family history of cancer particularly with regard to the
type of cancer and the age at onset in the relative. This
was further worsened by the breaking up of the joint
family system in urban India. 
Once the Clinic started functioning, we tried to
circumvent some of the problems, by providing the
proband with the questionnaire and asking him/her to
complete it in consultation with the elders in the family
who  may  not  be  staying  with  them.  In  addition,
wherever doubts existed with regard to the site and type
of cancer, the individuals were counselled on the need
to obtain old records. The success rate with this was
directly  proportional  to  the  anxiety  in  the
family/proband about the cancer in the family being
hereditary in origin. In spite of this, in at least 15% of
cases, particularly from the lower socio-economic
group, information regarding their first-degree relatives
may not be available and this percentage increases to
above 30% for second-degree relatives. 
The off-take of the gene testing services was much
above our expectations, at nearly 95%. However, this is
tempered by the relatively low interest to know the result
of the gene tests. This indicates also the undercurrent of
anxiety in individuals and their families about having
a deleterious  mutation  detected.  While  the  Clinic
discusses the issues related to gene testing and the
follow-up measures required in the event of a deleterious
mutation being detected, and the risk to the siblings and
their children, it apparently is not sufficient to allay all
the fears they have. In addition, the understanding of
the implications in the uneducated needs to be further
improved. However, the social issues are unlikely to be
overcome  in  the  near  future  and  this  will  require
community education on the general aspects of cancer
and the curability of cancer when detected early. 
One of the families seen and tested exemplifies the
current realities in the lower middle income group. This
family had the mother and her daughter affected with
colorectal cancer and a novel splice junction mutation
was detected in both. A letter was sent to the family
asking them to report to the Institute. A week later the
family reported and the results were announced after
taking an informed consent for knowing the results.
The family was counselled with regard to the follow-
up measures to be followed by the affected mother and
the daughter. There were two other siblings younger
than the affected daughter and both were offered
predictive testing. Although the family wanted the
predictive testing done, they wanted it deferred for
some  time.  The  family  also  requested  that  no
communication be sent to their residence as it was
a joint family and none of the other residents knew
about the illness the daughter had. The family wanted
to proceed with the marriage arrangements for the
affected daughter and sought our opinion. Since the
daughter had hardly completed a year after her initial
treatment, she was advised against this. Subsequent to
this, in deference to the wishes of the family, we have
not communicated with the family for further follow-up
and it is quite likely that the affected daughter has had
her marriage completed. 
This contrasts with an educated upper middle class
family, wherein the brother of an affected patient with
HNPCC not only convinced his sister to undergo the gene
testing, but once a deleterious abnormality was detected
in her, had himself tested (he had a keratocanthoma). He
was also found to be a carrier of the same mutation and
was counselled with regard to the follow-up measures,
which he undertook shortly thereafter. He then convinced
his two other sisters to undergo predictive testing, who
when tested did not carry the same mutation. 
The establishment and running of the country's first
comprehensive hereditary cancer clinic has thrown up
surprises and challenges. The challenges will need to
be addressed keeping the sensitivities of the population
in mind. 
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